RESEARCHER PROFILE
Professor Kristofer Thurecht, Deputy Director of Research & Senior
Group leader, Australian Institute for Bioengineering and Nanotechnology,
University of Queensland, Australia
Finding better ways of treating cancer, aside from finding a cure, aim to provide a better quality of life for those who suffer from it.
Professor Thurecht’s work focuses on nanomedicine and spans across the Australian Institute for Bioengineering and Nanotechnology and the Centre for Advanced Imaging, at the University of Queensland in Australia.
Professor Thurecht undertook his PhD at the University of Queensland and decided he wanted to go to the University of Nottingham in the UK, where his mentors pushed him into the new field of nanomedicine. On returning to Australia he brought his ideas on nanomedicine back to the University of Queensland, where he works today.
His research focuses on understanding how nanomedicines behave in biological environments using high-end imaging infrastructure, with a focus on radiopharmaceutical research to establish next generation drugs for diseases like cancer.
Nanomedicine research, particularly in the field of cancer treatment, has the potential to revolutionise traditional medicine and improve the quality of life for those suffering from the disease. Radiopharmaceuticals and molecular imaging are revolutionising cancer treatment by providing targeted therapies and precise drug delivery, showing potential for groundbreaking advancements in the field.
Radiopharmaceuticals utilise radiation as a potent therapy for treating diseases, particularly cancer. As Professor Thurecht states, the development of radiopharmaceutical for cancer treatment is a promising and innovative field in nanomedicine.
Outside of research Professor Thurecht enjoys fishing and boating with family on weekends.
You Might also like
-
Next-generation NK cell-based immunotherapies for hard-to-treat cancers
Associate Professor Fernando Guimaraes is an internationally recognised leader in cancer immunotherapy and natural killer (NK) cell biology. Based at The University of Queensland, he leads innovative research focused on developing next-generation NK cell-based immunotherapies for hard-to-treat cancers, including sarcomas and neuroblastoma.
-
Understanding the experience of pain for novel brain-based treatments
Associate Professor Tasha Stanton leads the Persistent Pain Research Group at SAHMRI. She is also co-Director of IIMPACT in Health at the University of South Australia, Adelaide. She is a clinical pain neuroscientist, with original training as a physiotherapist, and her research focusses on pain – why do we have it and why doesn’t it go away?
-
Engineering bacteria to detect colorectal cancer cells
An international team of researchers from Adelaide and the United States has engineered bacteria capable of detecting mutated DNA released from colorectal cancer cells, opening the door to faster disease detection.